Compare ADMA Biologics Inc (ADMA) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? ADMA Biologics Inc trades at $9.25 (market cap $2.13B), while Norwegian Cruise Line Holdings Ltd trades at $18.24 (market cap $8.65B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 4.1× ADMA Biologics Inc's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | NCLH | |
|---|---|---|
Market Cap | $2.13B | $8.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $26.94 |
52-Week Low | $7.60 | $14.79 |
Enterprise Value | $2.20B | $23.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
NCLH trades at $18.83, down 4.8% on the day, reflecting near-term pressure amid a bearish technical signal. The company has demonstrated consistent earnings beats, with Q1 2026 EPS of $0.23 exceeding the $0.15 estimate. Fundamentals show a P/E of 15.53 and a net income margin of 5.66%, while recent news highlights new executive appointments and future cruise itineraries. The stock is trading below the consensus analyst price target of $22.00.
The outlook is mixed; strong earnings performance and a favorable valuation offer upside potential, but high debt levels and a bearish technical trend present significant risks. The stock's performance is closely tied to travel demand and macroeconomic factors affecting the cruise industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
